Morgan Stanley has upgraded Bausch + Lomb Corp (BLCO) to Overweight from Equal-Weight, reflecting a more optimistic outlook on the company's prospects. This adjustment, effective December 1, 2025, comes as Bausch + Lomb, a key player in the health care sector, continues to navigate its three operational segments: Vision Care, Pharmaceuticals, and Surgical. The company, headquartered in Vaughan, Ontario, develops, manufactures, and markets a range of eye health products and currently employs 13,500 full-time staff.
As of the latest financial snapshot, Bausch + Lomb has a market capitalization of $5.3 billion and reported a trailing twelve-month earnings per share (EPS) of -0.86. The company is slated to announce its upcoming earnings on February 13, 2026, with analysts estimating an EPS of $0.36 and revenue of $1.4 billion.
The recent upgrade underscores a shift in analyst sentiment, potentially indicating improved fundamentals or a more favorable business performance. Analyst ratings, which consist of professional opinions based on extensive research, can provide valuable insights but should be considered alongside various factors such as competitive positioning and industry trends.
Currently, the analyst consensus on Bausch + Lomb stands at Buy, with three Strong Buy, seven Buy, nine Hold, one Sell, and no Strong Sell ratings. This reflects a diverse range of opinions within the analyst community, highlighting that ratings can evolve as new information emerges.